[Form 4] Inspire Medical Systems, Inc. Insider Trading Activity

Inspire Medical Systems director reports stock compensation.

Rhea-AI Filing Summary

Inspire Medical Systems director reports stock compensation. Director Georgia Melenikiotou reported acquiring 180 shares of Inspire Medical Systems common stock on 01/15/2026 at a price of $96.47 per share. These shares were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, meaning board fees were paid in stock instead of cash. Following this transaction, Melenikiotou beneficially owned 4,166 shares of Inspire Medical Systems common stock, held directly.

Insider Trade Summary

Grant/Award: 180 shares

Grant/Award 1 txn

Insider Melenikiotou Georgia

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	180	$96.47	$17K

Holdings After Transaction: Common Stock — 4,166 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who reported a transaction in Inspire Medical Systems (INSP) stock?

Director Georgia Melenikiotou reported a transaction in Inspire Medical Systems, Inc. common stock on a Form 4 filing.

How many Inspire Medical Systems (INSP) shares did the director receive?

The director received 180 shares of Inspire Medical Systems common stock in the reported transaction.

What was the price per share for the reported Inspire Medical Systems (INSP) transaction?

The reported price per share was $96.47 for the 180 shares of Inspire Medical Systems common stock.

Why did the Inspire Medical Systems (INSP) director receive these shares?

The shares were received in lieu of cash fees under Inspire Medical Systems’ Non-Employee Director Compensation Policy.

How many Inspire Medical Systems (INSP) shares does the director own after this transaction?

After the transaction, the director beneficially owned 4,166 shares of Inspire Medical Systems common stock, held directly.

Was this Inspire Medical Systems (INSP) Form 4 filed for one reporting person or multiple?

The Form 4 was filed by one reporting person, director Georgia Melenikiotou.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/20/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Melenikiotou Georgia

(Last) (First) (Middle)

C/O INSPIRE MEDICAL SYSTEMS, INC.

5500 WAYZATA BLVD., SUITE 1600

(Street)

GOLDEN VALLEY MN 55416

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inspire Medical Systems, Inc. [ INSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		A		180(1)	A	$96.47	4,166	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.

	/s/ Bryan Phillips, Attorney-in-Fact for Georgia Melenikiotou	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.